Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $18.7 million.

  • Insight Molecular Diagnostics' Cash & Equivalents rose 450.00% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 450.00%. This contributed to the annual value of $8.6 million for FY2024, which is 8.44% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Cash & Equivalents stood at $18.7 million, which was down 23.05% from $24.3 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Cash & Equivalents high stood at $58.9 million for Q1 2021, and its period low was $3.4 million during Q3 2024.
  • Its 3-year average for Cash & Equivalents is $14.2 million, with a median of $11.6 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 75.36% in 2024, then surged by 454.09% in 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Cash & Equivalents (Quarterly) stood at $32.9 million in 2021, then slumped by 39.32% to $20.0 million in 2022, then crashed by 52.82% to $9.4 million in 2023, then decreased by 8.44% to $8.6 million in 2024, then spiked by 450.00% to $18.7 million in 2025.
  • Its last three reported values are $18.7 million in Q3 2025, $24.3 million for Q2 2025, and $31.0 million during Q1 2025.